UNSPSC 51361801: Dexmedetomidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67VB76HONO, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, (r)- but generally known as dexmedetomidine, which bears US NIH Compound Identifier 60612. European Medicines Agency schedules Dexmedetomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07037MIG.

UNSPSC 51361801 Dexmedetomidine (Commodity) covers a sedative and analgesic pharmaceutical product that state and local governments procure primarily through cooperative purchasing agreements and direct competitive bidding for use in community health, emergency response, and pharmacy benefit programs. Recent opportunities show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment capacity — work that spans county health departments, state health and human services commissions, and multistate cooperative purchasing alliances managing pharmacy benefit programs across participating jurisdictions.

Recent activity includes Seminole County, Florida's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023) with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission's RFI (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, covering participating states including Oregon and distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Minnesota cooperative procurement weights price competitiveness at 75 percent, requires cGMP and Drug Supply Chain Security Act certification, and mandates $2 million to $5 million insurance coverage thresholds. Geographic spread spans Florida, Texas, Minnesota, and Oregon, with activity concentrated among state health agencies, county health departments, and regional cooperative purchasing vehicles.